Study Reveals How EBV Triggers MS Immune Response
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Kjetil Bjornevik led a study published in Science Translational Medicine on Wednesday showing how Epstein-Barr virus activates immune responses that drive inflammation and nervous system damage in multiple sclerosis.
- Harvard T.H. Chan School of Public Health researchers provided mechanistic evidence linking Epstein-Barr virus infection to the autoimmune processes central to MS development.
- Epstein-Barr virus initiates immune reactions that mistakenly target the nervous system, according to the study’s findings, clarifying a long-observed epidemiological association.
- Multiple Sclerosis Center of Rhode Island director Syed Rizvi, not involved in the study, said the research advances the potential for highly targeted drug development in MS treatment.
Why it matters: The study shifts MS research from correlation to mechanism, giving drug developers concrete immune pathways to target. This could lead to therapies that prevent or manage MS without relying on broad immunosuppressants, reducing side effects for patients and accelerating vaccine or antiviral development efforts focused on Epstein-Barr virus.
